Cart
sales@molnova.com
(R)-(-)-Rolipram
CAS No. 85416-75-7
(R)-(-)-Rolipram( R)-Rolipram | (-)-Rolipram )
Catalog No. M16203 CAS No. 85416-75-7
A more active enantiomer of the PDE4 inhibitor rolipram.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 92 | In Stock |
|
| 2MG | 37 | In Stock |
|
| 5MG | 59 | In Stock |
|
| 10MG | 93 | In Stock |
|
| 25MG | 180 | In Stock |
|
| 50MG | 327 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(R)-(-)-Rolipram
-
NoteResearch use only, not for human use.
-
Brief DescriptionA more active enantiomer of the PDE4 inhibitor rolipram.
-
DescriptionA more active enantiomer of the PDE4 inhibitor rolipram; shows 2-10-fold more potent than the S-(+) enantiomer rolipram.Asthma Phase 2 Clinical.
-
In VitroThe increase of cAMP synthesis with the adenylate cyclase activator forskolin or the decrease of cAMP hydrolysis by the phosphodiesterase inhibitors Isobutylmethylxanthine (IBMX) and (R)-(-)-Rolipram suppresses caspase-1 cleavage and IL-1β secretion in a dose-dependent manner.
-
In Vivo——
-
SynonymsR)-Rolipram | (-)-Rolipram
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research AreaInflammation/Immunology
-
IndicationAsthma
Chemical Information
-
CAS Number85416-75-7
-
Formula Weight275.3428
-
Molecular FormulaC16H21NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 49 mg/mL
-
SMILESCOC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3
-
Chemical Name2-Pyrrolidinone, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-, (4R)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Schneider HH, et al. Eur J Pharmacol. 1986 Aug 7;127(1-2):105-15.
2. Owens RJ, et al. Biochem J. 1997 Aug 15;326 ( Pt 1):53-60.
3. Ohsawa F, et al. Jpn J Pharmacol. 1998 Jun;77(2):147-54.
molnova catalog
related products
-
Tovinontrine
Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment.
-
GEBR-7b
GEBR-7b is a phosphodiesterase-4 (PDE4) inhibitor.
-
Rolipram
A potent, selective inhibitor of phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.
